Two different dosages of yeast derived recombinant hepatitis B vaccines: a comparison of immunogenicity

Chiaramonte, M.; Majori, Silvia; Ngatchu, Theodore; Moschen, Maria Elisa; Baldo, Vincenzo; Renzulli, G; Simoncello, I; Rocco, S.; Bertin, T.; Naccarato, R.; Trivello, R.

doi:10.1016/0264-410x(95)00148-t

Cited by 27 publications

(16 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This result was consistent with the findings from previous research studies. 16,17 Maintaining seroprotection rates at year 23 were significantly associated with vaccine response at early stages (i.e., anti-HBs levels at year 1 and year 11) as identified by multivariate logistic regression. This can be explained by the possibility that the and a subsequent test.…”

Section: Resultsmentioning

confidence: 99%

“…Two studies reported that participants receiving 20 μg dosage developed a higher antibody level after a month of last dose of vaccination than those receiving 10 μg dosage. 11,13 However, Gilbert et al observed that vaccination with 10 μg of recombinant HBV vaccine may provide a clinically effective alternative to the standard 20 μg dose in healthy adolescents.…”

Section: Resultsmentioning

confidence: 99%

“…9,10 However, participants receiving 20 μg of vaccine have been found to have higher antibody levels than those receiving 10 μg vaccine in some studies. 11 Despite several research endeavors, there is very little knowledge about the long-term seroprotection following different doses of vaccine.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Comparison of long-term immunogenicity (23 y) of 10 μg and 20 μg doses of hepatitis B vaccine in healthy children

Zhuang

Wang

et al. 2012

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of long-term immunogenicity (23 y) of 10 μg and 20 μg doses of hepatitis B vaccine in healthy children

Zhuang

Wang

et al. 2012

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

“…[58][59] However, participants receiving 20 mg of vaccine have been found to have higher antibody levels than those receiving 10 mg vaccine in some studies. [60][61] Conflicting reports from previous studies comparing the efficacy of HepB have been observed. However, Gilbert et al observed that vaccination with 10 mg of recombinant HBV vaccine may provide a clinically effective alternative to the standard 20 mg dose in healthy adolescents.…”

Section: Discussionmentioning

confidence: 99%

24 year outcomes of hepatitis B vaccination in Hangzhou, China

Xu²,

Wang³

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

To evaluate the impact of the universal infant HepB vaccination program on hepatitis B virus infection in Hangzhou, China. Hepatitis B incidences and HepB vaccination rates of Hangzhou from 1990 to 2003 were acquired from the historical paper-documents, while which were derived from China Information System for Diseases Control and , P < 0.001). Significant association was found between incidence of hepatitis B and HepB vaccination rate (r D 0 .946, x 2 D 11.813, P for trend D 0.001). A total of 5605 participants aged 0-59 y included in this serological survey. The prevalence of HBsAg, anti-HBs, anti-HBc, HBeAg and anti-HBe were 6.19%, 45.83%, 57.25%, 0.62%, and 4.37%, respectively. Hangzhou has successfully integrated the HepB into routine immunization programs and this has had a significant impact on decreasing the incidence of hepatitis B infection.

show abstract

“…From published data [5][6][7][8][9][10][11][12][13][14][37][38][39][40][41][42][43] and national vaccination guidelines, 29,43 we anticipated that the protection rate in healthy normal younger adults would be 90% to 95% with the standard 3-dose regimen of current single antigen vaccines, and because this study allowed all ages to be recruited with randomization stratified for age group (above or below 40 years) to ensure balance, we anticipated that the overall Engerix-B protection rate would be at the lower end of the above range.…”

Section: Methodsmentioning

confidence: 99%

Adult Hepatitis B Vaccination Using A Novel Triple Antigen Recombinant Vaccine

Young¹,

Schneider

Zuckerman

et al. 2001

Hepatology

View full text Add to dashboard Cite

Present hepatitis B vaccines use multidose prolonged regimens, which even healthcare workers at risk do not always complete. Moreover, when vaccination is completed there remain some who fail to achieve adequate protection. The protection of adults at risk could be improved if there were a more potent vaccine and/or a shorter vaccination regimen available. Vaccine-naive adults were randomized to vaccination with either Engerix-B (SmithKline Biologicals, Rixensart, Belgium) or a novel triple antigen (S, pre-S1, and pre-S2) recombinant vaccine (Hepacare; Medeva Pharma Plc, Speke, UK). The primary efficacy parameter was the degree of seroprotection 6 or 7 months (26 ؎ 2 weeks) after beginning vaccination. A total of 304 adults entered the study. Of these, 16 failed to complete the study (9 on Hepacare and 7 on Engerix-B). With the Engerix-B standard (0, 1, 6) regimen, 88% of subjects were protected by month 7, whereas with the triple antigen vaccine a 2-dose regimen (0, 1) provided equivalent protection (91%) within 6 months and a 3-dose (0, 1, 6) regimen was significantly superior (98% seroprotected by 7 months after starting vaccination P < .001). With adults at risk for a suboptimal response (i.e., older adults, the obese, men, and smokers) the triple antigen vaccine produced a greater degree of protection. The vaccines had similar safety profiles. Both vaccines were well tolerated. In healthy normal adults, a triple antigen hepatitis B vaccine containing S and pre-S antigens produced an enhanced immunologic response and was as effective as a 2-and 3-dose regimen. (HEPATOLOGY 2001;34:372-376.)Although hepatitis B is largely a disease of the developing world, it is still a problem in the developed world. The estimated annual incidence of new infections of hepatitis B in the United States has varied from 200,000 to 300,000 new cases each year over the past decade. 1-3 Much of the disease is subclinical and a recent estimate 4 has suggested some 6-fold under-reporting with a true incidence of 1,000,000 new cases every year in Europe alone. All this is despite the availability of vaccines for over 2 decades.Although much of the problem has been the limited population in whom the vaccine was used initially there are other issues. First, all hepatitis B vaccines to date show a decreased response in certain subjects such as older adults, men, smokers, and the obese as well as when given intradermally or in the buttocks rather than in the deltoid muscle. [5][6][7][8][9][10][11][12][13][14][15][16][17][18][19] Second, present vaccines are usually given in a 6-month/3-dose (0, 1, and 6 months) regimen. 20,21 This implies that protection is not provided to a significant number of adults until some 7 months after beginning a course of vaccination. The implication is reinforced by the development of a so-called "accelerated course" of 3 doses given within 2 months (0, 1, and 2 months) for those who require rapid protection. 20,22 Unfortunately, this course does not deliver longer-term protection, and a booster dose at 12 mon...

show abstract

Two different dosages of yeast derived recombinant hepatitis B vaccines: a comparison of immunogenicity

Cited by 27 publications

References 7 publications

Comparison of long-term immunogenicity (23 y) of 10 μg and 20 μg doses of hepatitis B vaccine in healthy children

Comparison of long-term immunogenicity (23 y) of 10 μg and 20 μg doses of hepatitis B vaccine in healthy children

24 year outcomes of hepatitis B vaccination in Hangzhou, China

Adult Hepatitis B Vaccination Using A Novel Triple Antigen Recombinant Vaccine

Contact Info

Product

Resources

About